1. Name and Address of Reporting Person*  
Wilfong Diane E.  
(Last) (First) (Middle)  
GILEAD SCIENCES, INC.  
333 LAKESIDE DRIVE  
(Foreign Name)  
(Foreign Address)  
City, State, Zip  
(GILEASCIENCES INC GILD)  
2. Issuer Name and Ticker or Trading Symbol  
GILEAD SCIENCES INC [ GILD ]  
3. Date of Earliest Transaction (Month/Day/Year)  
02/06/2022  
4. If Amendment, Date of Original Filed  
(Month/Day/Year)  
5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
Director  
Officer (give title below)  
SVP, Controller & CAO  
6. Individual or Joint/Group Filing (Check Applicable Line)  
Form filed by One Reporting Person  
Form filed by More than One Reporting Person  
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  
<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>02/06/2022</td>
<td></td>
<td>M</td>
<td>1,864 A</td>
<td>$24,739</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>02/06/2022</td>
<td></td>
<td>F</td>
<td>520 D</td>
<td>$24,219</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  
<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit (1)</td>
<td>02/06/2022</td>
<td></td>
<td>M</td>
<td>1,864 (2)</td>
<td>Common Stock</td>
<td>1,864 (1)</td>
<td>14,043</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:  
1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.’s common stock.  
2. The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

As/ Amy Kim by Power of  
Attorney for Diane E. Wilfong 02/08/2022  
** Signature of Reporting Person  
Date  
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.